CNS Drug Discoveries: Depression Chapter

Published by: Espicom Healthcare Intelligence

Published: Aug. 14, 2008 - 88 Pages

Table of Contents

DEPRESSION

EXECUTIVE SUMMARY

THE.FACTS

What.is.depression.and.why.are.we.interested.in.it?

PATIENT STATISTICS

Incidence,.diagnosis.rates.and.treatment;.now.and.in.the.future

PATIENT MODEL

Summary of Depression Patient Population Forecasts in Seven Major Markets (2007E-2014E)

Model.Assumptions

DRUG GROWTH DRIVERS

DRUG GROWTH RISKS/DAMPENERS

THE.ANTIDEPRESSANT.MARKET

Global CNS Market 2007 (US$91.9 billion)

Global Sales Split by Drug Class (2007A)

Global Sales Split by Region (2006)

The.Major.Players.Products.in.2007

Market Share of Antidepressant Players by Sales (Dec 2007A)

The.Major.Players.and.Products.in.2014

Market Share of Antidepressant Players by Sales (Dec 2014E)

CURRENT.TREATMENTS

Leading.Brands

Comparison of Leading Antidepressant Drugs

Current.Products'.Patent.Exposure

Patent Exposure of Leading Antidepressant Brands

ANALYSIS OF LEADING BRANDS

Selective.Serotonin.Reuptake.Inhibitors.(SSRIs)

Lexapro/Cipralex

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Prozac

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Seroxat/Paxil

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Zoloft

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Serotonin.and.Noradrenaline.Reuptake.Inhibitors.(SNRIs)

Cymbalta

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Effexor

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Pristiq

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Noradrenaline.and.Dopamine.Reuptake.Inhibitors.(NDRIs)

Wellbutrin

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2007A - 2014E

Sales Forecasts of Current Leading Antidepressant Drugs

Model.Assumptions

NEW.DRUGS.IN.R&D

Drugs in Development to Treat Depression and Anxiety Related Disorders

ANALYSIS OF PHASE III DRUGS

New Drugs in Phase III Development to Treat Depression and Anxiety

Neurokinin.Receptor.Antagonist

Saredutant

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Melatonergic.Receptor.Agonist

Valdoxan

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical experience

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Other.Late-Phase.Drugs

Amibegron

Seroquel

Vilazodone

GLOBAL SALES FORECASTS OF PHASE III ANTIDEPRESSANT AND ANTI-ANXIETY DRUGS 2009E - 2014E

Sales Forecasts of Phase III Developmental Drugs for Depression and Anxiety

Model.Assumptions

ANALYSIS OF PHASE II DRUGS

New Drugs in Early Clinical Development to Treat Depression and Anxiety

Triple.Uptake.Inhibitor

NS2359

Novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

Competition within the market-place/gaining share of voice

Risks associated with developing a drug within a therapeutic class

Filings and approval

Sales forecasts and assumptions

Competitor ratio analysis

Other.Phase.II.Drugs.of.Interest

DOV 21,947

MN-305

GLOBAL SALES FORECASTS OF PHASE II ANTIDEPRESSANT DRUGS 2010E - 2014E

Sales Forecasts of Phase II Developmental Antidepressant Drugs

Model.Assumptions

COMPETITOR.RATIO.ANALYSIS

COMPETITOR RATIO ANALYSIS - PRODUCTS

CR Analysis of Antidepressant Agents Approved by 2014 - Based on Drug Class

COMPETITOR RATIO ANALYSIS - COMPANIES

CR Analysis of Antidepressant Agents Approved by 2014 - Based on Company

WINNERS & LOSERS

Summary of Key Companies and Drugs in the Antidepressant Market by 2014

Winners

Losers

DISCONTINUATION.OF.DRUGS

Antidepressants/Anxiolytics Discontinued from Clinical Development

DEPRESSION.APPENDIX.1

ASSESSMENT OF DEPRESSION CRITERIA

DEPRESSION.APPENDIX.2

PHASE TRANSITION PROBABILITY

Probability of Launch

DEPRESSION.APPENDIX.3

PATIENT MODEL

Summary of US Depression and Anxiety Patient Population Forecasts

Summary of Europe (Top 5) Depression and Anxiety Patient Population Forecasts

Summary of Japanese Depression and Anxiety Patient Population Forecasts

DEPRESSION.APPENDIX.4

GLOBAL ANTIDEPRESSANT DRUGS SALES 2007A-20014E

DEPRESSION.APPENDIX.5

COMPETITOR RATIO ANALYSIS CRITERIA

Key Antidepressant/Anxiolytic Drugs on the Market by 2014

DEPRESSION.GLOSSARY

DEPRESSION.REFERENCES

ACRONYMS

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.